Tiziana announces publication of a peer reviewed article on data from the clinical trial with intranasally administered foralumab, its proprietary fully human anti-cd3 monoclonal antibody, in mild to moderate covid-19 patients in brazil

New york and london, aug. 17, 2021 (globe newswire) -- tiziana life sciences plc (nasdaq: tlsa / lse: tils) ("tiziana" or the "company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces publication of a scientific article in the peer-reviewed journal frontiers in immunology titled " nasal administration of anti-cd3 monoclonal antibody (foralumab) reduces lung inflammation and blood inflammatory biomarkers in mild to moderate covid-19 patients: a pilot study "(1). the study was completed in collaboration with scientific teams at the harvard medical school (boston, usa) and intrials, a full-service latin american cro based in sÃo paulo, brazil. the aim of the study was to assess safety of intranasal foralumab and evaluate its potential benefits in treating immune hyperactivity and lung inflammation in mild to moderate covid-19 patients who were outpatients at the santa casa de misericordia de santos hospital in brazil. thirty-nine patients were randomized into three cohorts: no foralumab treatment (control), nasal foralumab (100 ug) + dexamethasone (6 mg orally on days 1-3), and nasal foralumab (100 ug) alone administered for 10 consecutive days. all arms were allowed to continue standard of care medications. to view the online publication, please click here: http://journal.frontiersin.org/article/10.3389/fimmu.2021.709861/full?&utm_source=email_to_authors_&utm_medium=email&utm_content=t1_11.5e1_author&utm_campaign=email_publication&field=&journalname=frontiers_in_immunology&id=709861
TLSA Ratings Summary
TLSA Quant Ranking